-
BioMarin hemophilia A gene therapy phase 3 follow-up data update, perhaps it is time to re-understand the "persistence" of efficacy
Time of Update: 2023-02-01
January 12, 2023 /eMedClub News/-- BioMarin today announced its AAV gene therapy Roctavian for the treatment of hemophilia A Valectocogene Roxaparvovec) has yielded positive results in Phase 3 clinical trials and has been followed for more than 3 years.
-
Primary immune thrombocytopenia needs to be "treated" according to the person, and the first-line, second-line, and third-line treatment methods are summarized here→
Time of Update: 2023-02-01
Poke "Read Original" to see moreWhen it comes to primary immune thrombocytopenia (ITP), doctors and friends must be familiar with it, "at least 2 consecutive blood routine tests show a decrease in platelet count (< 100×109/L) [1]" The incidence is about (2~10)/100,000 people, and most of the people over 60 years old and women of childbearing age [2, 3].
-
2023 CASH| Professor Xiao Zhijian: Accurate diagnosis of blood diseases has a long way to go, and LDT helps China enter a new era of accurate diagnosis
Time of Update: 2023-02-01
Professor Xiao ZhijianPrecision medicine mainly includes precision diagnosis and precision treatment, without accurate diagnosis, there is no precision treatment, but at present, China's accurate diagnosis of blood pathology still faces some problems: First, some new diagnostic technologies, such as second-generation flow cytometry (NGF), second-generation sequencing (NGS), digital PCR and single-cell and spatial omics, are inseparable from laboratory self-built detection (LDT).
-
Can the microthrombosis hypothesis explain the symptoms of long new crown? Long article "Nature"
Time of Update: 2023-02-01
Originally written by Cassandra WillyardSome patients choose to try risky treatments because of a microthrombus hypothesis, and scientists have mixed opinions on the evidence behind it. Lara Hawthorne
-
2022CSH Professor Xia Linghui: Progress in the prevention and treatment of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML/MDS patients
Time of Update: 2023-01-07
At this conference, Professor Xia Linghui from the Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, introduced the current status and prevention strategies of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with the topic of "Progress in the prevention and control of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML/MDS patients".
-
2022CSH Professor Cai Qingqing: Treatment progress of NK/T-cell lymphoma
Time of Update: 2023-01-07
Yimaitong edited and sorted, please do not reprint without authorization. The 17th National Hematology Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25,
-
Conference Preview 2022 CSCO Annual Conference Harbin Branch &The 7th Anti-Leukemia and Lymphoma International Summit Forum invites you to attend (November 10-11)
Time of Update: 2023-01-07
In this conference, a number of academic sessions such as academician forum, leukemia and lymphoma session, lymphoma youth forum, leukemia youth forum, children's blood special session, tumor-related anemia forum and other academic special sessions were set up, and famous experts and scholars in the field of hematological oncology at home and abroad were specially invited to discuss basic research, cutting-edge progress and hot topics in the fields of leukemia, lymphoma, myeloma and myelodysplastic syndrome (MDS) at home and abroad.
-
Talents gathered together to climb the academic "peak" of ASCT - CSCO Autologous Transplantation Working Group 2022 Lecture-Lymphoma Special Session (Anhui Station) was a complete success
Time of Update: 2023-01-07
On October 9, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour - Lymphoma Special Session (Anhui Station), hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Exp
-
2022 SHS stands at the head of the tide, strives to be the first, discusses the frontier of blood, explores the road to the future, and the 15th Suzhou Hematology Summit is grandly held!
Time of Update: 2023-01-07
In front of the south window of Qiulan, the fragrance is quiet. On October 8, 2022, many top hematology experts at home and abroad gathered in Gusu City, a paradise on earth, to participate in the 15t
-
Famous people are getting better and better, riding on the momentum, gathering momentum and strengthening, advancing the lymphoma diagnosis and treatment center of Zheng Dayi Affiliated Hospital
Time of Update: 2023-01-07
" ——Professor Zhang Lei In addition to large-scale academic activities, the Lymphoma Diagnosis and Treatment Center of Zhengda First Affiliated Hospital holds MDT academic activities every 2-4 weeks, with the participation of personnel from relevant departments inside and outside the province, such as oncology, pathology, radiotherapy, laboratory medicine, and imaging, and the format of the conference includes special lectures, case discussions, consultation of difficult cases and scientific research collaboration.
-
Expanding life, Worun hopes that I will accurately compose the chapter of life, Topshuwo ® (Avounibu Tablets) China Listing Conference · East China & Central China Station was successfully held
Time of Update: 2023-01-07
The golden qi is at the autumn equinox, and the rain in the gorge falls. CStone Pharmaceuticals' world's first IDH1 inhibitor, Tosuvo ® (ivoranib tablets), has entered clinical application in China, f
-
2022 SHS Chief Nurse Zhu Xiaming: Pass on the experience of blood disease nursing in the First Affiliated Hospital of SUSU University to escort patients' health
Time of Update: 2023-01-07
At the "2022 Suzhou Hematology Summit and National Continuing Medical Education Class" held in Suzhou on October 7-9, 2022, Yimaitong specially invited Zhu Xiaming, chief nurse of the First Affiliated Hospital of Soochow University, to share the nursing work of hematopoietic stem cell transplantation (HSCT) and the nursing team of the First Affiliated Hospital of Soochow University on the nursing experience of patients with blood diseases.
-
The journey is long, the struggle is timely——CSCO Autologous Transplantation Working Group 2022 Tour (Suzhou Station) was a complete success
Time of Update: 2023-01-07
On October 17, 2022, the "CSCO Autologous Transplantation Working Group 2022 Tour - Suzhou Station" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee, CSCO Leuk
-
2022CSH Professor Zhang Huilai: "No chemotherapy" improves the quality of life of patients with indolent lymphoma, and precise stratification brings the dawn of cure to R/R patients
Time of Update: 2023-01-07
Yimaitong edited and sorted, please do not reprint without authorization. The 17th National Hematology Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25,
-
Case evaluation Professor Hou Ming: The combination of two swords and walls has begun to show strength, the blade out of the sheath to accurately block elderly AML, and the treatment of FLT3 mutant AML by geratinib can be expected in the future
Time of Update: 2023-01-06
05×10 9/L, HGB 54g/L, PLT 7×109/L, combined with pulmonary infection, cardiac insufficiency, treated with meropenem, tigecycline, voriconazole, improved, and considered adjusting the 。Myelocytology: CRFlow cytometry: abnormal myeloid cells < 0.
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Micro-classroom No. 16 Professor Ma Yanping: Discussion on maintenance therapy suitable for transplanted NDMM patients
Time of Update: 2023-01-06
Autologous hematopoietic stem cell transplantation (ASCT) remains the standard of care for patients with multiple myeloma (TE NDMM) who are candidates for transplantation. In the era of new drugs, sma
-
Professor Qiu Lin: Dynamic monitoring of mutant genes, NGS to help AML personalized precision treatment| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Next-generation sequencing (NGS) plays an important role in the prognosis analysis, efficacy evaluation, recurrence prediction and detection of minimal residual disease (MRD) in acute myeloid leukemia
-
Yi Shuo Blood New Time and Space Gathering Chinese and foreign forces, talking about multidisciplinary progress, MM International Exchange Conference was grandly held
Time of Update: 2023-01-06
The content is rich and rewarding, I hope that all colleagues, especially young doctors, will ponder this repeatedly and move forward firmly!At the end of the conference, Professor Chen Wenming, the chairman of the conference, concluded that the conference showed the considerable results of clinical trials, and then sublimated to real-world patient data statistics, and explained in detail the treatment strategies of MM and the development of high-quality real-world research through Sino-foreign exchanges and interdisciplinary sharing.
